Repligen Corporation (RGEN) P/E Ratio History
Historical price-to-earnings valuation from 2005 to 2026
Loading P/E history...
RGEN Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Repligen Corporation (RGEN) trades at a price-to-earnings ratio of 147.0x, with a stock price of $126.43 and trailing twelve-month earnings per share of $0.91.
The current P/E is 73% below its 5-year average of 552.9x. Over the past five years, RGEN's P/E has ranged from a low of 52.3x to a high of 6683.5x, placing the current valuation at the 60th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, RGEN trades at a 559% premium to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, RGEN commands a significant premium over the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our RGEN DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
RGEN P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $4B | 9.9Lowest | - | +68%Best | |
| $10B | 13.1 | 1.87Best | +29% | |
| $11B | 47.5 | - | -14% | |
| $8B | 110.7 | - | -56% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
RGEN Historical P/E Data (2005–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q1 | $117.82 | $0.90 | 130.9x | -45% | |
| FY2025 Q4 | Wed Dec 31 2025 00:00:00 GM | $163.86 | $0.85 | 192.8x | -20% |
| FY2025 Q3 | $133.67 | $0.02 | 6683.5x | +2685% | |
| FY2025 Q2 | Mon Jun 30 2025 00:00:00 GM | $124.38 | $0.08 | 1554.8x | +548% |
| FY2024 Q1 | Sun Mar 31 2024 00:00:00 GM | $183.92 | $0.25 | 735.7x | +207% |
| FY2023 Q4 | Sun Dec 31 2023 00:00:00 GM | $179.80 | $0.72 | 249.7x | +4% |
| FY2023 Q3 | Sat Sep 30 2023 00:00:00 GM | $159.01 | $2.03 | 78.3x | -67% |
| FY2023 Q2 | Fri Jun 30 2023 00:00:00 GM | $141.46 | $2.42 | 58.5x | -76% |
| FY2023 Q1 | Fri Mar 31 2023 00:00:00 GM | $168.36 | $2.95 | 57.1x | -76% |
| FY2022 Q4 | Sat Dec 31 2022 00:00:00 GM | $169.31 | $3.24 | 52.3x | -78% |
| FY2022 Q3 | Fri Sep 30 2022 00:00:00 GM | $187.11 | $2.89 | 64.7x | -73% |
| FY2022 Q2 | $162.40 | $2.76 | 58.8x | -75% |
Average P/E for displayed period: 240.0x
See RGEN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs RGEN Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare RGEN vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonRGEN — Frequently Asked Questions
Quick answers to the most common questions about buying RGEN stock.
Is RGEN stock overvalued or undervalued?
RGEN trades at 147.0x P/E, below its 5-year average of 552.9x. At the 60th percentile of historical range, the stock is priced at a discount to its own history.
How does RGEN's valuation compare to peers?
Repligen Corporation P/E of 147.0x compares to sector median of 22.3x. The premium reflects expected growth above peers.
What is RGEN's PEG ratio?
RGEN PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2005-2026.